Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN

Royal Bank of Canada grew its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 267.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 68,188 shares of the company’s stock after purchasing an additional 49,641 shares during the quarter. Royal Bank of Canada’s holdings in Dyne Therapeutics were worth $1,236,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the 1st quarter valued at $26,000. Strs Ohio bought a new stake in Dyne Therapeutics in the 4th quarter worth $51,000. Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics in the 4th quarter worth $84,000. Steward Partners Investment Advisory LLC increased its position in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 3.0%

Shares of Dyne Therapeutics stock opened at $25.98 on Friday. The company has a 50-day simple moving average of $23.52 and a two-hundred day simple moving average of $19.73. The stock has a market capitalization of $4.85 billion, a PE ratio of -7.80 and a beta of 1.07. Dyne Therapeutics, Inc. has a 52-week low of $11.65 and a 52-week high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of analyst reports. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Cantor Fitzgerald initiated coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the sale, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner bought 2,500 shares of Dyne Therapeutics stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $17.48 per share, with a total value of $43,700.00. Following the acquisition, the director owned 22,500 shares in the company, valued at approximately $393,300. This represents a 12.50% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 6,500 shares of company stock worth $114,000 and sold 4,139,196 shares worth $99,449,852. Corporate insiders own 9.46% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.